Castle Biosciences (NASDAQ:CSTL) Price Target Raised to $44.00

Posted by Brenda Bartman on Aug 6th, 2026

Castle Biosciences (NASDAQ:CSTL – Free Report) had its price objective lifted by BTIG Research from $40.00 to $44.00 in a research report released on Monday morning, Marketbeat reports. The firm currently has a buy rating on the stock.

CSTL has been the subject of a number of other reports. Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 26th. KeyCorp set a $35.00 target price on Castle Biosciences in a research report on Friday, May 29th. Robert W. Baird set a $36.00 price target on shares of Castle Biosciences in a research note on Friday, July 31st. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings upgraded shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.00.

View Our Latest Analysis on Castle Biosciences

Castle Biosciences Price Performance

NASDAQ:CSTL opened at $30.40 on Monday. Castle Biosciences has a 52 week low of $17.72 and a 52 week high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $928.72 million, a PE ratio of -46.06 and a beta of 0.98. The stock’s 50-day moving average price is $23.38 and its 200-day moving average price is $26.23.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. As a group, equities analysts expect that Castle Biosciences will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling at Castle Biosciences

In other news, COO Kristen M. Oelschlager sold 8,587 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $20.71, for a total value of $177,836.77. Following the transaction, the chief operating officer owned 30,460 shares in the company, valued at $630,826.60. This trade represents a 21.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Tobin W. Juvenal sold 17,310 shares of Castle Biosciences stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $29.31, for a total value of $507,356.10. Following the completion of the sale, the insider directly owned 80,725 shares in the company, valued at $2,366,049.75. This represents a 17.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 101,461 shares of company stock valued at $2,713,541 over the last quarter. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after buying an additional 27,511 shares in the last quarter. RTW Investments LP acquired a new position in Castle Biosciences during the fourth quarter worth about $82,283,000. Principal Financial Group Inc. boosted its position in Castle Biosciences by 0.7% during the fourth quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after acquiring an additional 13,289 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Castle Biosciences by 7.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after acquiring an additional 96,084 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC raised its holdings in Castle Biosciences by 164.7% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Key Headlines Impacting Castle Biosciences

Here are the key news stories impacting Castle Biosciences this week:

Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The revised target indicates substantial potential upside and reflects confidence in Castle Biosciences’ diagnostic-testing growth outlook. BTIG raises Castle Biosciences price target
Positive Sentiment: Castle Biosciences’ latest quarterly results exceeded expectations, with revenue of $99.86 million versus the $86.23 million analyst consensus and a loss of $0.07 per share versus expectations for a $0.41 loss. The results support the case for improving operating performance, although the company remains unprofitable.
Neutral Sentiment: Recent coverage highlighted developments involving Castle Biosciences’ diagnostics business, but the available details do not indicate whether the update will materially affect revenue, earnings or reimbursement expectations. Castle Biosciences diagnostics update
Negative Sentiment: Multiple insiders disclosed stock sales totaling approximately $1.68 million. Derek J. Maetzold sold 28,646 shares, COO Kristen M. Oelschlager sold 8,586 shares, and Tobin W. Juvenal sold 19,040 shares in transactions conducted from July 31 through August 3. The sales reduced their holdings and may weigh on investor sentiment, particularly after the stock’s recent strength. However, all reported transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal than discretionary sales. Castle Biosciences insider sales filing

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.